Burkitt Lymphoma: all 407 studies
Page 3 of 5. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's LymphomaCompletedNCT00392834Phase 2Results posted
- PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaCompletedNCT00303953Phase 2Results posted
- CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
- Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
- Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00278408Phase 3Results posted
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaCompletedNCT00133991Phase 2Results posted
- Intensive Chemotherapy and Rituximab in the Treatment of Burkitt LymphomaTerminatedNCT00126191Phase 2Results posted
- Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00119392Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073918Phase 2Results posted
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00058019Phase 2Results posted
- Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or LymphomaCompletedNCT00057811Phase 2Results posted
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's LeukemiaCompletedNCT00039130Phase 2Results posted
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00001337Phase 2Results posted
- Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic LeukemiaActive, not recruitingNCT07199855Phase 2
- BAFFR CAR-T Treatment for Relapsed/Refractory B-cell TumorsWithdrawnNCT07196111Early Phase 1
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT07153796Phase 1/2
- A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT07134088Phase 1/2
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedNCT06738368Phase 2
- Pre-emptive Anakinra for Cytokine Event ReductionWithdrawnNCT06703216Phase 1/2
- A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
- Diabetes, Metabolic Syndrome and Risk of Malaria in CameroonCompletedNCT06278181
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T TherapiesActive, not recruitingNCT06220097Phase 2
- CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic LeukemiaCompletedNCT06027957Phase 1
- A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)WithdrawnNCT06009107Phase 1/2
- CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionActive, not recruitingNCT05707273Phase 1
- GastroIntestinal Cancer in Children and AdolescentsStatus unknownNCT05693519
- ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesCompletedNCT05653271Phase 1
- Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALLStatus unknownNCT05639179Phase 1/2
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaActive, not recruitingNCT05602194Phase 3
- Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
- CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLActive, not recruitingNCT05470777Phase 2
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruitingNCT05460533Phase 2
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaActive, not recruitingNCT05453500Phase 2
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
- Natural Killer (NK) Cell Therapy for B-Cell MalignanciesStatus unknownNCT05379647Phase 1
- Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT05303792Phase 2
- Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesActive, not recruitingNCT05270057Phase 1
- Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingNCT05263583Phase 2
- NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALLTerminatedNCT05262673Phase 1
- Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT05157971Phase 1
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruitingNCT05020678Phase 1
- Venetoclax Plus Inotuzumab for B-ALLActive, not recruitingNCT05016947Phase 1
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALLActive, not recruitingNCT04690595Phase 1
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
- A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Active, not recruitingNCT04404660Phase 1/2
- Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
- Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
- A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyActive, not recruitingNCT04148430Phase 2
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaTerminatedNCT03913559Phase 2
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingNCT03876769Phase 2
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 1
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaTerminatedNCT03808610Phase 1/2
- A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedNCT03793140Phase 2
- Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03779854Phase 2
- ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT03698552Phase 1/2
- Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and BlinatumomabCompletedNCT03480438Phase 2
- Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseActive, not recruitingNCT03441061Phase 2
- CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and LymphomaStatus unknownNCT03298828Phase 1
- Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell LymphomaStatus unknownNCT03281551Phase 1
- Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03241940Phase 1
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03233854Phase 1
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03007147Phase 3
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingNCT02981628Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric OncologyCompletedNCT02847130
- A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell LymphomaWithdrawnNCT02776891Phase 2
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedNCT02723994Phase 2
- A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's LymphomaStatus unknownNCT02585947Phase 4
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesCompletedNCT02315612Phase 1
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic LeukemiaActive, not recruitingNCT02146924Phase 1
- Yoga Fatigue StudyTerminatedNCT02134782Not applicable